In light of the current COVID-19 situation, the COEDC is thankful to all the local businesses that are going above and beyond in supporting the community. Thank you Lexaria Bioscience for your leadership.
A Kelowna company that specializes in blood stream drug delivery technology is investigating how it might help in the COVID-19 battle.
Lexaria Bioscience, whose headquarters are on McCurdy Road, has expanded the scope and activities of its subsidiary, Lexaria Pharmaceutical Corp., to investigate how the company’s patented DehydraTech drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against the new coronavirus.
Lexaria said its technology, which essentially gets drugs into the blood stream quicker and through smaller doses, could save money and improve accessibility of drug doses.
“Furthermore, DehydraTECH’s bioavailability enhancing effects are believed to be enabled in part by influencing a decrease in first pass liver metabolism for orally administered drugs,” the company said in a press release. “This, in turn, is thought to enable improved safety and tolerability for patients by maximizing the quantity of the ingested drug that traverses the (gastrointestinal) tract and reaches the bloodstream without being degraded by or placing stress upon organs that process waste elimination.”
Lexaria intends to expand collaboration with leading laboratories in North America and internationally as soon as possible.
For more information, visit Lexaria Bioscience: https://www.lexariabioscience.com/